EP0000028A1 - Process for the preparation of a water-insoluble enzyme composition - Google Patents
Process for the preparation of a water-insoluble enzyme composition Download PDFInfo
- Publication number
- EP0000028A1 EP0000028A1 EP78100045A EP78100045A EP0000028A1 EP 0000028 A1 EP0000028 A1 EP 0000028A1 EP 78100045 A EP78100045 A EP 78100045A EP 78100045 A EP78100045 A EP 78100045A EP 0000028 A1 EP0000028 A1 EP 0000028A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- enzyme
- carrier
- preparation
- activity
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004190 Enzymes Human genes 0.000 title claims abstract description 60
- 108090000790 Enzymes Proteins 0.000 title claims abstract description 60
- 238000002360 preparation method Methods 0.000 title claims abstract description 40
- 238000000034 method Methods 0.000 title claims abstract description 31
- 230000000694 effects Effects 0.000 claims abstract description 39
- 239000011148 porous material Substances 0.000 claims abstract description 25
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 claims abstract description 18
- 108700040099 Xylose isomerases Proteins 0.000 claims abstract description 18
- 125000000524 functional group Chemical group 0.000 claims abstract description 7
- 238000013459 approach Methods 0.000 claims abstract description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 5
- 229920006395 saturated elastomer Polymers 0.000 claims description 4
- 239000003513 alkali Substances 0.000 claims description 2
- 238000000137 annealing Methods 0.000 claims description 2
- 229940088598 enzyme Drugs 0.000 abstract description 48
- 239000000969 carrier Substances 0.000 abstract description 13
- 229940079919 digestives enzyme preparation Drugs 0.000 abstract description 7
- 239000000243 solution Substances 0.000 description 25
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 12
- 239000008363 phosphate buffer Substances 0.000 description 12
- 239000008055 phosphate buffer solution Substances 0.000 description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 239000000758 substrate Substances 0.000 description 5
- 239000007822 coupling agent Substances 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 3
- 239000004115 Sodium Silicate Substances 0.000 description 3
- 238000007873 sieving Methods 0.000 description 3
- 229910000077 silane Inorganic materials 0.000 description 3
- NTHWMYGWWRZVTN-UHFFFAOYSA-N sodium silicate Chemical compound [Na+].[Na+].[O-][Si]([O-])=O NTHWMYGWWRZVTN-UHFFFAOYSA-N 0.000 description 3
- 229910052911 sodium silicate Inorganic materials 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 229910004298 SiO 2 Inorganic materials 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- WDMUXYQIMRDWRC-UHFFFAOYSA-N 2-hydroxy-3,4-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=C([N+]([O-])=O)C([N+]([O-])=O)=C1O WDMUXYQIMRDWRC-UHFFFAOYSA-N 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108010093096 Immobilized Enzymes Proteins 0.000 description 1
- 108090000769 Isomerases Proteins 0.000 description 1
- 102000004195 Isomerases Human genes 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 229940025131 amylases Drugs 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- MGNCLNQXLYJVJD-UHFFFAOYSA-N cyanuric chloride Chemical compound ClC1=NC(Cl)=NC(Cl)=N1 MGNCLNQXLYJVJD-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 108010042194 dextransucrase Proteins 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- -1 hydroxylapatite, silicates Chemical class 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229910000480 nickel oxide Inorganic materials 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- GNRSAWUEBMWBQH-UHFFFAOYSA-N oxonickel Chemical compound [Ni]=O GNRSAWUEBMWBQH-UHFFFAOYSA-N 0.000 description 1
- RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical compound [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000005373 porous glass Substances 0.000 description 1
- 238000004886 process control Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 150000004756 silanes Chemical class 0.000 description 1
- 238000002444 silanisation Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 229920003176 water-insoluble polymer Polymers 0.000 description 1
- 229910001928 zirconium oxide Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
- C12N11/14—Enzymes or microbial cells immobilised on or in an inorganic carrier
Definitions
- the invention relates to a process for the preparation of water-insoluble enzyme preparations and enzyme preparations produced thereafter. It is known to immobilize enzymes by binding to organic or inorganic carriers, ie to render them water-insoluble, so that they are reusable and can be used in continuously operating processes.
- Organic materials e.g. cellulose, nylon, polyacrylamide
- cellulose, nylon, polyacrylamide have considerable disadvantages as carriers because they do not have sufficient mechanical stability, can be attacked by the solvent, are sensitive to changing pH values and ionic strengths, and in some cases tend to attack microbes, causing the bond to Enzyme can be dissolved.
- inorganic substances have been proposed as carriers on which enzymes are bound by adsorption or covalently.
- the preferred type of binding depends on the type and conditions of use of the enzyme and the nature of the substrate. If, for example, the substrate is in a high salt concentration, the adsorption method cannot be used because desorption of the adsorbed enzyme molecules is possible. Therefore, the covalent binding of the enzyme to the carrier is preferred.
- the carrier surface must then contain specific functional groups that ensure binding of the enzyme. Since the carrier does not have these functional groups in most cases, the surface must be pretreated. For example, the coating of inorganic material with silanes is known, as a result of which the surface is given organic functional groups (for example alkylamine) which contain organic sub punch a covalent bond.
- Aluminum oxide, nickel oxide, iron oxide, titanium oxide, zirconium oxide, hydroxylapatite, silicates and porous glass have been proposed as the material for inorganic carriers, the pore structure of which ensures the accessibility of the enzyme and the substrate to the inner surface, in addition to their other desirable properties, e.g. optimal pore distribution and surface size, however, there are very different information.
- the invention is therefore based on the object of improving the known processes for the preparation of water-insoluble enzyme preparations, in which an inorganic carrier having functional groups for covalent bonding is brought into contact with an enzyme solution, so that a maximally active preparation is obtained with minimal enzyme expenditure.
- This object is achieved according to the invention by selecting a carrier with such a most common pore diameter which, regardless of the amount of enzyme bound to it, results in a preparation with maximum activity, and by bringing the carrier selected in this way into contact with an enzyme solution which contains only enough enzyme that the specific activity of the preparation produced with it reaches or comes close to the specific activity of the enzyme in the free state.
- carriers with different common pore diameters are first provided with coupling agents according to known methods, which both adhere sufficiently firmly to the carrier, in particular form a covalent bond to the carrier, and are capable of covalent binding with the enzyme.
- coupling agents according to known methods, which both adhere sufficiently firmly to the carrier, in particular form a covalent bond to the carrier, and are capable of covalent binding with the enzyme.
- silanization has become the most common method for inorganic carriers, but, as already mentioned, other coupling agents can also be used.
- the number of coupling links on the carrier must be sufficiently large and largely depends on the surface of the carrier.
- the carriers pretreated in this way are then offered different amounts of enzyme by bringing them into contact with enzyme solutions of different concentrations and by covalent binding of the enzyme to the coupling member and thus to the carrier by known methods.
- Determination of the activity of the preparations thus obtained shows that the activity of the preparations depends on the most common pore diameter regardless of the amount of enzyme bound to them and runs through a maximum.
- the grain size of the carrier is irrelevant to the position of the maximum and at best influences its absolute value.
- the grain size of the carrier has therefore only of secondary importance for the teaching according to the invention and largely depends on the intended use, for example the viscosity of the substrate, the process control and the like.
- the optimal carrier determined in this way with regard to the most common pore diameter is then again offered different amounts of enzyme. It is shown that preparations are obtained at certain enzyme concentrations, the specific activity of which approaches or reaches the specific activity of the enzyme in the free state, i.e. the relative activity of the preparation reaches a value of 100%.
- the optimum carrier can be obtained according to a further development of the invention if the gel, after setting an alkali content, calculated as Na 2 0 and based on dry substance, from 0.1 to 0, 5 wt .-%, and drying, 5 to 10 hours in a steam-containing air stream at 400 0 C to 850 ° C, preferably 570 0 C to 750 ° C, glows.
- the drying is expediently carried out in water vapor-saturated air at 180 ° C. to 200 ° C.
- a water vapor-containing air stream with a relative humidity of 40 to 80% has proven to be advantageous for annealing.
- the carrier thus produced has a most common pore diameter of 175 to 3,000 ⁇ , preferably 250 to 600 ⁇ , optimally about 340 ⁇ .
- the immobilization method according to the invention can be used for all technically and analytically important enzymes, for example for hydrolases (eg amylases, glycosidases, proteases), oxidoreductases (glucose oxidase, catalase), Isomerases (glucose isomerase), transferases (dextran sucrase).
- hydrolases eg amylases, glycosidases, proteases
- oxidoreductases glucose oxidase, catalase
- Isomerases glucose isomerase
- transferases dextran sucrase
- the optimal preparation is obtained when the optimal carrier is brought into contact with a solution which is 25 to 75 mg , preferably 50 mg, contains amyloglucosidase per gram of carrier.
- the optimal preparation is obtained if the optimal carrier is brought into contact with a solution containing 20-50 mg, preferably 25 mg, of glucose isomerase per Grams of carrier contains.
- the carrier 1 For the preparation of the carrier 1 a precipitated from sodium silicate solution with sulfuric acid was dried Si0 2 gel having a Na 2 0 content of 0.3 wt .-% at 180 0 C in water vapor saturated air for three hours. 1 kg of this material was annealed for six hours at 730 ° C. in an air stream of 2 l / min, which had a relative moisture content of 80%. After this treatment, the SiO 2 had a common pore diameter of 1400 ⁇ . Carrier 1 was separated into fractions by sieving. The further preparation was carried out with the fraction 0.25 to 0.5 mm.
- sample 1.2 10 g of silanized carrier 1 were suspended in 20 ml solution of 0.5 g amyloglucosidase (Merck 1330) in 0.05 m phosphate buffer (pH 7). The further procedure corresponded to the preparation of sample 1.1. The C-N analysis of the finished sample 1.2 showed a protein content of 9.0 mg / g.
- Si0 2 gel having a Na 2 0 content of 0.3 wt .-% as in Example 1 dried. 1 kg of this material was annealed for 6 hours at 680 ° C in an air flow of 2 1 / min, which had a relative moisture content of 80%. After this treatment, the SiO 2 has a mode pore diameter of 340 ⁇ had. The carrier 2 was separated into fractions by sieving. The further preparation was carried out with the fraction 0.25 to 0.5 mm.
- Carrier 2 calculated on the basis of the mean value of the C and N determination, contained 0.19 m eq of silane / g.
- silanized carrier 2 Another 10 g of the silanized carrier 2 were suspended in 20 ml solution of 0.5 g amyloglucosidase (Merck 1330) in 0.05 m phosphate buffer (pH 7) and treated as described in Example 1 (sample 1.2).
- the CN analysis of the finished sample 2.2 showed a protein content of 17.4 mg / g.
- Si0 2 gel having a Na 2 0 content of 0.3 wt .-% as in Example 1 dried. 1 kg of this material was annealed for six hours at 640 ° C in an air flow of 2 l / min, which had a relative moisture content of 60%. After this treatment, the Si0 2 had a common pore diameter of 180 ⁇ . The carrier 3 was separated into fractions by sieving. The further preparation was carried out with the fraction 0.25 to 0.50 mm.
- Carrier 3 calculated on the basis of the mean value of the C and N determination, contained 0.51 m eq of silane / g.
- the finished sample 3.1 had a protein content of 26.2 mg / g after the C-N analysis.
- a further 10 g of the silanized carrier 3 were suspended in 20 ml of a solution of 0.5 g of amyloglucosidase (Merck 1330) in 0.05 m phosphate buffer (pH 7) and treated as described in Example 1 (sample 1.2).
- the C-N analysis of the finished sample 3.2 showed a protein content of 12.7 mg / g.
- the fraction 0.25-0.5 mm was sieved from the carrier 2 (most common pore diameter 340 ⁇ ) and 50 g thereof in 500 ml 12.5 % aqueous glutardialdehyde solution stirred for 5 minutes at room temperature. 500 ml of saturated NH 4 C1 solution were then added. After four hours of stirring at room temperature, the sample was washed with water until free of chloride and dried over P 2 0 5 in vacuo. 10 g of this carrier were suspended in 20 ml solution of 1 g amyloglucosidase (Merck 1330) in 0.05 m phosphate buffer (pH 7) and prepared as described in Example 1.
- the finished sample 4.1 had a protein content of 29.8 mg / g after the C-N analysis.
- the reaction time was 30 minutes at room temperature. After every 10 minutes, the reaction vessel was evacuated and, after the reaction had ended, the residual solution was suctioned off. Then 3 washes with water and 0.05 m phosphate buffer (pH 7).
- the finished sample 5.1 had a protein content of 4.8 mg / g after the C-N analysis.
- the C-N analysis of the finished sample 5.2 showed a protein content of 2.0 mg / g.
- the further treatment corresponded to Example 5.
- the finished sample 6.1 had a protein content of 22.0 mg / g after the C-N analysis.
- sample 6.2 a further 10 g of carrier 2 were suspended in 40 ml of a 0.05 m phosphate buffer solution (pH 7) which contained 0.25 g of glucose isomerase.
- the further treatment corresponded to example 5.
- the C-N analysis of the finished sample 6.2 showed a protein content of 10.2 mg / g.
- the further treatment corresponded to Example 5.
- the finished sample 7.1 had a protein content of 11.2 mg / g after the C-N analysis.
- the C-N analysis of the finished sample 7.2 showed a protein content of 5.1 mg / g.
- Example 5 10 g of the carrier mentioned in Example 4 (most common pore diameter 340 ⁇ , treated with aqueous glutardialdehyde solution) were suspended in 40 ml of a 0.05 M phosphate buffer solution (pH 7), which contained 0.5 g of glucose isomerase. The further treatment corresponded to Example 5.
- the finished sample 8.1 had a protein content of 21.3 mg / g after the C-N analysis.
- sample 8.2 a further 10 g of the same carrier were suspended in 40 ml of a 0.05 m phosphate buffer solution (pH 7) which contained 0.25 g of glucose isomerase. The further procedure corresponded to preparation 5.1. The C-N analysis of the finished sample 8.2 showed a protein content of 9.8 mg / g.
- the activity of the preparations 1.1, 1.2 described in Examples 1 to 4; 2.1, 2.2; 3.1, 3.2; 4.1, 4.2 and that of the enzyme used for fixation was used according to the dinitrosalicylic acid method (see Rick, W., Stegbauer, HP in: Bergmeyer, HU "Meth. D. Enzymatic Analysis", Verlag Chemie 1970 S. 848 ff).
- One activity unit (U) corresponds to the amount of enzyme that releases 1 ⁇ equivalent reducing groups (calculated as glucose) per minute under incubation conditions.
- the protein content of the preparations was determined on the basis of the mean values of the C-N determination.
- the most common pore diameter of the carriers was determined from the pore distribution (measured with a high pressure porosimeter).
- the protein content of the preparations was determined on the basis of the mean values of the C-N determination.
- the method according to the invention has for the first time made it possible to use expensive enzymes technically, since the method allows the use of carrier according to the invention to optimize the amount of enzyme required for maximum activity.
Landscapes
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Gegenstand der Erfindung ist ein Verfahren zur Herstellung von wasserunlöslichen Enzympräparaten. Erfindungsgemäß werden anorganische Träger mit unterschiedlichem häufigsten Porendurchmesser zunächst nach an sich bekannten Verfahren mit zur Bindung des Enzyms an den Träger befähigten funktionellen Gruppen versehen und aus den so funktionalisierten Trägern nach an sich bekannten Verfahren Enzympräparate hergestellt, indem man den unterschiedlichen Trägern unterschiedliche Mengen an Enzym anbietet. Dabei zeigt sich, daß die absolute Aktivität der erhaltenen Präparate ungeachtet der an sie gebundenen Enzymmenge vom häufigsten Porendurchmesser des Trägers abhängig ist und für einen bestimmten häufigsten Porendurchmesser ein Maximum durchläuft. Anschließend werden aus dem hinsichtlich seines häufigsten Porendurchmessers ermittelten optimalen Träger Enzympräparate hergestellt, indem man diesem Träger unterschiedliche Mengen an Enzym anbietet. Dabei zeigt sich, daß bei einem bestimmten Enzymangebot die spezifische Aktivität des Präparats der spezifischen Aktivität des Enzyms im freien Zustand nahekommt oder diese erreicht. Es läßt sich somit die für ein Präparat mit maximaler Aktivität benötigte Enzymmenge optimieren. Gegenstand der Erfindung sind außerdem nach dem Verfahren hergestellte Enzympräparate mit Amyloglucosidase- bzw. Glucoseisomerase-Aktivität.The invention relates to a process for the preparation of water-insoluble enzyme preparations. According to the invention, inorganic carriers with different common pore diameters are first provided with functional groups capable of binding the enzyme to the carrier according to methods known per se, and enzyme preparations are produced from the functionalized carriers according to methods known per se by offering different amounts of enzyme to the different carriers . It is shown that the absolute activity of the preparations obtained, regardless of the amount of enzyme bound to them, depends on the most common pore diameter of the carrier and runs through a maximum for a certain most common pore diameter. Subsequently, enzyme preparations are made from the optimal carrier determined with regard to its most common pore diameter by offering this carrier different amounts of enzyme. It can be seen that, with a certain enzyme supply, the specific activity of the preparation approaches or reaches the specific activity of the enzyme in the free state. The amount of enzyme required for a preparation with maximum activity can thus be optimized. The invention also relates to enzyme preparations produced by the process and having amyloglucosidase or glucose isomerase activity.
Description
Die Erfindung betrifft ein Verfahren zur Herstellung wasserunlöslicher Enzympräparate und danach hergestellte Enzympräparate.
Es ist bekannt, Enzyme durch Bindung an organische oder anorganische Träger zu immobilisieren, d.h. wasserunlöslich zu machen, so dass diese wiederverwendbar sind und in kontinuierlich arbeitenden Verfahren eingesetzt werden können.The invention relates to a process for the preparation of water-insoluble enzyme preparations and enzyme preparations produced thereafter.
It is known to immobilize enzymes by binding to organic or inorganic carriers, ie to render them water-insoluble, so that they are reusable and can be used in continuously operating processes.
Organische Materialien (z.B. Zellulose, Nylon, Polyacrylamid) weisen als Träger erhebliche Nachteile auf, da sie keine ausreichende mechanische Stabilität besitzen, vom Lösungsmittel angegriffen werden können, gegenüber wechselnden pH-Werten und Ionenstärken empfindlich sind und teilweise zum Mikrobenbefall neigen, wodurch die Bindung zum Enzym gelöst werden kann.Organic materials (e.g. cellulose, nylon, polyacrylamide) have considerable disadvantages as carriers because they do not have sufficient mechanical stability, can be attacked by the solvent, are sensitive to changing pH values and ionic strengths, and in some cases tend to attack microbes, causing the bond to Enzyme can be dissolved.
Deshalb wurden anorganische Substanzen als Träger vorgeschlagen, auf denen Enzyme adsorptiv oder kovalent gebunden werden. Die bevorzugte Art der Bindung hängt von der Art und den Einsatzbedingungen des Enzyms und der Beschaffenheit des Substrates ab. Liegt das Substrat beispielsweise in einer starken Salzkonzentration vor, ist die Adsorptionsmethode nicht anwendbar, da eine Desorption der adsorbierten Enzymmoleküle möglich ist. Deshalb wird die kovalente Bindung des Enzyms an den Träger vorgezogen. Die Trägeroberfläche muss dann spezifische funktionelle Gruppen enthalten, die eine Bindung des Enzyms gewährleisten. Da der Träger diese funktionellen Gruppen in den meisten Fällen nicht besitzt, ist eine Vorbehandlung der Oberfläche erforderlich. Bekannt ist beispielsweise die Belegung von anorganischem Material mit Silanen, wodurch die Oberfläche organisch funktionelle Gruppen (z.B. Alkylamin) erhält, die mit organischer Substanz eine kovalente Bindung eingehen. Weiterhin ist die Behandlung anorganischer Träger mit Sulfurylchlorid, Thionylchlorid oder Cyanurchlorid erprobt worden. Ausserdem ist es möglich, die Trägeroberfläche mit einem wasserunlöslichen Polymer zu überziehen, das freie funktionelle Gruppen aufweist, wie z.B. Polyacrolein, das zwischen 10 und 70 % freie Aldehydgruppen, bezogen auf die Anzahl der monomeren Moleküle, besitzt.Therefore, inorganic substances have been proposed as carriers on which enzymes are bound by adsorption or covalently. The preferred type of binding depends on the type and conditions of use of the enzyme and the nature of the substrate. If, for example, the substrate is in a high salt concentration, the adsorption method cannot be used because desorption of the adsorbed enzyme molecules is possible. Therefore, the covalent binding of the enzyme to the carrier is preferred. The carrier surface must then contain specific functional groups that ensure binding of the enzyme. Since the carrier does not have these functional groups in most cases, the surface must be pretreated. For example, the coating of inorganic material with silanes is known, as a result of which the surface is given organic functional groups (for example alkylamine) which contain organic sub punch a covalent bond. The treatment of inorganic supports with sulfuryl chloride, thionyl chloride or cyanuric chloride has also been tried. In addition, it is possible to coat the support surface with a water-insoluble polymer which has free functional groups, such as polyacrolein, which has between 10 and 70% free aldehyde groups, based on the number of monomer molecules.
Als Material für anorganischeTräger wurden Aluminiumoxide, Nickeloxid, Eisenoxid, Titanoxid, Zirkonoxid, Hydroxylapatit, Silikate und poröses Glas vorgeschlagen, deren Porenstruktur die Zugänglichkeit des Enzyms und des Substrates zur inneren Oberfläche gewährleistet, über deren weitere wünschenswerte Eigenschaften, wie z.B. optimale Porenverteilung und Oberflächengrösse jedoch sehr unterschiedliche Angaben vorliegen.Aluminum oxide, nickel oxide, iron oxide, titanium oxide, zirconium oxide, hydroxylapatite, silicates and porous glass have been proposed as the material for inorganic carriers, the pore structure of which ensures the accessibility of the enzyme and the substrate to the inner surface, in addition to their other desirable properties, e.g. optimal pore distribution and surface size, however, there are very different information.
Mit keinem der genannten Träger gelang es, unabhängig von der angewandten Bindungsart, Enzyme so zu immobilisieren, dass ihre spezifische Aktivität der spezifischen Aktivität im freien Zustand nahekommt. Nach Angaben von D.L.Latigue (Immobilized Enzymes for Industrial Reactors, London 1975, S. 127) liegen auch unter besten Immobilisierungsbedingungen nur maximal 80 % des auf dem Träger aufgebrachten Enzyms in aktiver Form vor.Regardless of the type of binding used, none of the carriers mentioned succeeded in immobilizing enzymes in such a way that their specific activity comes close to the specific activity in the free state. According to D.L. Latigue (Immobilized Enzymes for Industrial Reactors, London 1975, p. 127), even under the best immobilization conditions, only a maximum of 80% of the enzyme applied to the carrier is present in active form.
Der Erfindung liegt daher die Aufgabe zugrunde, die bekannten Verfahren zur Herstellung wasserunlöslicher Enzympräparate, bei denen man einen anorganischen Träger mit funktionellen Gruppen zur kovalenten Bindung mit einer Enzymlösung in Berührung bringt, so zu verbessern, dass bei minimalem Enzymaufwand ein maximal aktives Präparat erhalten wird.The invention is therefore based on the object of improving the known processes for the preparation of water-insoluble enzyme preparations, in which an inorganic carrier having functional groups for covalent bonding is brought into contact with an enzyme solution, so that a maximally active preparation is obtained with minimal enzyme expenditure.
Die Lösung dieser Aufgabe gelingt gemäss der Erfindung dadurch, dass man einen Träger mit einem solchen häufigsten Porendurchmesser auswählt, der ungeachtet der an ihn gebundenen Enzymmenge ein Präparat mit maximaler Aktivität ergibt, und dass man den so ausgewählten Träger mit einer Enzymlösung in Berührung bringt, die nur so viel Enzym enthält, dass die spezifische Aktivität des damit hergestellten Präparats die spezifische Aktivität des Enzyms in freiem Zustand erreicht oder ihr nahekommt.This object is achieved according to the invention by selecting a carrier with such a most common pore diameter which, regardless of the amount of enzyme bound to it, results in a preparation with maximum activity, and by bringing the carrier selected in this way into contact with an enzyme solution which contains only enough enzyme that the specific activity of the preparation produced with it reaches or comes close to the specific activity of the enzyme in the free state.
Bei der Lehre nach der Erfindung werden zunächst Träger mit unterschiedlichen häufigsten Porendurchmessern nach bekannten Methoden mit Kupplungsmitteln versehen, die sowohl ausreichend fest am Träger haften, insbesondere eine kovalente Bindung zum Träger eingehen, als auch zu einer kovalenten Bindung mit dem Enzym befähigt sind. Als gebräuchlichste Methode hat sich in der Vergangenheit für anorganische Träger die Silanisierung durchgesetzt, es sind aber, wie schon ausgeführt, auch andere Kupplungsmittel einsetzbar. Die Anzahl der Kupplungsglieder am Träger muss hinreichend gross sein und hängt weitgehend von der Oberfläche des Trägers ab.In the teaching according to the invention, carriers with different common pore diameters are first provided with coupling agents according to known methods, which both adhere sufficiently firmly to the carrier, in particular form a covalent bond to the carrier, and are capable of covalent binding with the enzyme. In the past, silanization has become the most common method for inorganic carriers, but, as already mentioned, other coupling agents can also be used. The number of coupling links on the carrier must be sufficiently large and largely depends on the surface of the carrier.
Den so vorbehandelten Trägern werden dann unterschiedliche Enzymmengen angeboten, indem man sie mit Enzymlösungen unterschiedlicher Konzentration in Berührung bringt und nach bekannten Methoden eine kovalente Bindung des Enzyms zum Kupplungsglied und damit zum Träger herstellt. Nach. Bestimmung der Aktivität der so erhaltenen Präparate zeigt sich, dass die Aktivität der Präparate ungeachtet der an sie gebundenen Enzymmenge von dem häufigsten Porendurchmesser abhängt und ein Maximum durchläuft. Es hat sich dabei ausserdem gezeigt, dass die Korngrösse des Trägers für die Lage des Maximums unerheblich ist und allenfalls dessen Absolutwert beeinflusst. Die Korngrösse des Trägers hat daher für die Lehre nach der Erfindung nur eine untergeordnete Bedeutung und richtet sich weitgehend nach dem vorgesehenen Einsatzzweck, beispielsweise der Viskosität des Substrats, der Verfahrensführung und dgl.The carriers pretreated in this way are then offered different amounts of enzyme by bringing them into contact with enzyme solutions of different concentrations and by covalent binding of the enzyme to the coupling member and thus to the carrier by known methods. To. Determination of the activity of the preparations thus obtained shows that the activity of the preparations depends on the most common pore diameter regardless of the amount of enzyme bound to them and runs through a maximum. It has also been shown that the grain size of the carrier is irrelevant to the position of the maximum and at best influences its absolute value. The grain size of the carrier has therefore only of secondary importance for the teaching according to the invention and largely depends on the intended use, for example the viscosity of the substrate, the process control and the like.
Dem auf diese Weise hinsichtlich des häufigsten Porendurchmessers ermittelten optimalen Träger werden dann wiederum unterschiedliche Mengen Enzym angeboten. Dabei zeigt sich, dass bei bestimmten Enzymkonzentrationen Präparate erhalten werden, deren spezifische Aktivität der spezifischen Aktivität des Enzyms im freien Zustand nahekommt oder diese erreicht, d.h. die relative Aktivität des Präparats erreicht einen Wert von 100 %.The optimal carrier determined in this way with regard to the most common pore diameter is then again offered different amounts of enzyme. It is shown that preparations are obtained at certain enzyme concentrations, the specific activity of which approaches or reaches the specific activity of the enzyme in the free state, i.e. the relative activity of the preparation reaches a value of 100%.
Bei Trägern, die aus einem Si02-Gel hergestellt sind, lässt sich gemäss Weiterbildung der Erfindung der optimale Träger erhalten, wenn man das Gel nach Einstellung eines Alkaligehalts, berechnet als Na20 und bezogen auf Trockensubstanz, von 0,1 bis 0,5 Gew.-%, und Trocknung, 5 bis 10 Stunden in einem wasserdampfhaltigen Luftstrom bei 4000C bis 850°C, vorzugsweise 5700C bis 750°C, glüht.In the case of carriers which are produced from an Si0 2 gel, the optimum carrier can be obtained according to a further development of the invention if the gel, after setting an alkali content, calculated as Na 2 0 and based on dry substance, from 0.1 to 0, 5 wt .-%, and drying, 5 to 10 hours in a steam-containing air stream at 400 0 C to 850 ° C, preferably 570 0 C to 750 ° C, glows.
Zweckmässigerweise erfolgt die Trocknung in wasserdampfgesättigter Luft bei 180°C bis 200°C. Für das Glühen hat sich ein wasserdampfhaltiger Luftstrom mit einer relativen Feuchte von 40 bis 80 % als vorteilhaft erwiesen.The drying is expediently carried out in water vapor-saturated air at 180 ° C. to 200 ° C. A water vapor-containing air stream with a relative humidity of 40 to 80% has proven to be advantageous for annealing.
Der so hergestellte Träger weist einen häufigsten Porendurchmesser von 175 bis 3.000 Å, vorzugsweise 250 bis 600 Å, optimalerweise etwa 340 Å, auf.The carrier thus produced has a most common pore diameter of 175 to 3,000 Å, preferably 250 to 600 Å, optimally about 340 Å.
Das erfindungsgemässe Immobilisierungsverfahren ist für alle technisch und analytisch wichtigen Enzyme anwendbar, beispielsweise für Hydrolasen (z.B. Amylasen, Glycosidasen, Proteasen), Oxydoreductasen (Glucoseoxidase, Katalase), Isomerasen (Glucoseisomerase), Transferasen (Dextransucrase).The immobilization method according to the invention can be used for all technically and analytically important enzymes, for example for hydrolases (eg amylases, glycosidases, proteases), oxidoreductases (glucose oxidase, catalase), Isomerases (glucose isomerase), transferases (dextran sucrase).
Für den Fall, dass das Enzym Amyloglucosidase ist, welche im freien Zustand eine spezifische Aktivität von 10 bis 15 Einheiten/mg aufweist, wird das optimale Präparat dann erhalten, wenn man den optimalen Träger mit einer Lösung in Berührung bringt, die 25 bis 75 mg, vorzugsweise 50 mg, Amyloglucosidase pro Gramm Träger enthält.In the event that the enzyme is amyloglucosidase, which has a specific activity of 10 to 15 units / mg in the free state, the optimal preparation is obtained when the optimal carrier is brought into contact with a solution which is 25 to 75 mg , preferably 50 mg, contains amyloglucosidase per gram of carrier.
Wird als Enzym Glucoseisomerase eingesetzt, die im freien Zustand eine spezifischeAktivität von 50-70 Einheiten/mg aufweist, erhält man das optimale Präparat, wenn der optimale Träger mit einer Lösung in Berührung gebracht wird, die 20-50 mg, vorzugsweise 25 mg Glucoseisomerase pro Gramm Träger enthält.If glucose isomerase is used as the enzyme, which has a specific activity of 50-70 units / mg in the free state, the optimal preparation is obtained if the optimal carrier is brought into contact with a solution containing 20-50 mg, preferably 25 mg, of glucose isomerase per Grams of carrier contains.
Die nachfolgenden Beispiele dienen der Erläuterung der Erfindung.The following examples serve to explain the invention.
Zur Herstellung des Trägers 1 wurde ein aus Natriumsilikatlösung mit Schwefelsäure gefälltes Si02-Gel mit einem Na20-Gehalt von 0,3 Gew.-% bei 1800C in wasserdampfgesättigter Luft drei Stunden getrocknet. 1 kg dieses Materials wurde sechs Stunden bei 7300C in einem Luftstrom von 2 1/min, der einen relativen Feuchtigkeitsgehalt von 80 % aufwies, geglüht. Nach dieser Behandlung hatte das SiO2 einen häufigsten Porendurchmesser von 1400 Å. Der Träger 1 wurde durch Siebung in Fraktionen getrennt. Die weitere Präparation erfolgte mit der Fraktion 0,25 bis 0,5 mm.For the preparation of the carrier 1 a precipitated from sodium silicate solution with sulfuric acid was dried Si0 2 gel having a Na 2 0 content of 0.3 wt .-% at 180 0 C in water vapor saturated air for three hours. 1 kg of this material was annealed for six hours at 730 ° C. in an air stream of 2 l / min, which had a relative moisture content of 80%. After this treatment, the SiO 2 had a common pore diameter of 1400 Å. Carrier 1 was separated into fractions by sieving. The further preparation was carried out with the fraction 0.25 to 0.5 mm.
150 g dieser Trägerfraktion wurde 8 Stunden mit 4 1 einer 10 %igen Lösung von δ-Aminopropyltriäthoxysilan in Benzol am Rückfluss gekocht und nach Abkühlung mit je 1000 ml Benzol und mit je 1000 ml Aceton dreimal gewaschen. Nach Abdampfen des Lösungsmittels bei Raumtemperatur im Vakuum wurde der Träger zweimal mit 0,05 m Phosphatpuffer (pH 7) und dreimal mit bidest. Wasser gewaschen. Die Trocknung erfolgte über P205 im Vakuum. Berechnet auf Basis des Mittelwertes der C- und N-Bestimmung enthielt der Träger 1 0,13 m Äq Silan/g.150 g of this carrier fraction was refluxed for 8 hours with 4 l of a 10% solution of δ-aminopropyltriethoxysilane in benzene and, after cooling, washed three times with 1000 ml of benzene and with 1000 ml of acetone. After evaporating the solvent at room temperature in vacuo, the support was washed twice with 0.05 M phosphate buffer (pH 7) and three times with bidistilled. Washed water. Drying was carried out over P 2 0 5 in vacuo. Calculated on the basis of the mean value of the C and N determination, the support 1 contained 0.13 m eq of silane / g.
10 g dieses Trägers wurden in 20 ml Lösung von 1 g Amyloglucosidase (Merck 1330) in 0,05 m Phofphatpuffer (pH 7) suspendiert. Die Aktivität der Amyloglucosidase betrug 11,75 U/mg, wobei als Aktivitätsmass U die Bildung von 1/u Mol Glucose/min bei 25°C benutzt wurde. Die Suspension wurde 20 Minuten unter Vakuum gehalten, wieder belüftet und nach zwei Stunden nochmals für 20 Minuten evakuiert. Nach vier Stunden erfolgte die Trennung von Träger und Lösung durch Filtration, anschliessend dreimalige Waschung mit bidest. Wasser und schliesslich eine dreimalige Waschung mit 0,01 m Phosphatpuffer (pH 5). Die fertige Probe 1.1 wurde in Phosphatpuffer (pH 5) bei 4°C aufbewahrt. Die C-N-Analyse ergab einen Proteingehalt von 16,5 mg/g.10 g of this carrier were suspended in 20 ml solution of 1 g amyloglucosidase (Merck 1330) in 0.05 m phosphate buffer (pH 7). The activity of the amyloglucosidase was 11.75 U / mg, the activity measure U being the formation of 1 / u mol of glucose / min at 25 ° C. The suspension was kept under vacuum for 20 minutes, re-vented and, after two hours, again evacuated for 20 minutes. After four hours, the support and solution were separated by filtration, followed by three washes with bidist. Water and finally a three washes with 0.01 m phosphate buffer (pH 5). The finished sample 1.1 was stored in phosphate buffer (pH 5) at 4 ° C. The CN analysis showed a protein content of 16.5 mg / g.
Zur Herstellung der Probe 1.2 wurden 10 g des silanisierten Trägers 1 in 20 ml Lösung von 0,5 g Amyloglucosidase (Merck 1330) in 0,05 m Phosphatpuffer (pH 7) suspendiert. Die weitere Verfahrensweise entsprach der Präparation der Probe 1.1. Die C-N-Analyse der fertigen Probe 1.2 ergab einen Proteingehalt von 9,0 mg/g.To prepare sample 1.2, 10 g of silanized carrier 1 were suspended in 20 ml solution of 0.5 g amyloglucosidase (Merck 1330) in 0.05 m phosphate buffer (pH 7). The further procedure corresponded to the preparation of sample 1.1. The C-N analysis of the finished sample 1.2 showed a protein content of 9.0 mg / g.
Zur Herstellung des Trägers 2 wurde ein aus Natriumsilikatlösung mit Schwefelsäure gefälltes Si02-Gel mit einem Na20-Gehalt von 0,3 Gew.-%, wie im Beispiel 1 beschrieben, getrocknet. 1 kg dieses Materials wurde sechs Stunden bei 680°C in einem Luftstrom von 2 1/min, der einen relativen Feuchtigkeitsgehalt von 80 % aufwies, geglüht. Nach dieser Behandlung hatte das SiO2 einen häufigsten Porendurchmesser von 340 Å. Der Träger 2 wurde durch Siebung in Fraktionen getrennt. Die weitere Präparation erfolgte mit der Fraktion 0,25 bis 0,5 mm.For the preparation of the carrier 2 a precipitated from sodium silicate solution with sulfuric acid has been described Si0 2 gel having a Na 2 0 content of 0.3 wt .-% as in Example 1 dried. 1 kg of this material was annealed for 6 hours at 680 ° C in an air flow of 2 1 / min, which had a relative moisture content of 80%. After this treatment, the SiO 2 has a mode pore diameter of 340 Å had. The carrier 2 was separated into fractions by sieving. The further preparation was carried out with the fraction 0.25 to 0.5 mm.
150 g dieser Trägerfraktion wurde acht Stunden mit 4 1 einer 10 %igen Lösung von δ-Aminopropyltriäthoxysilan in Benzol entsprechend dem im Beispiel 1 angegebenen Verfahren behandelt.150 g of this carrier fraction was treated for 8 hours with 4 l of a 10% solution of δ-aminopropyltriethoxysilane in benzene in accordance with the procedure given in example 1.
Der Träger 2 enthielt, berechnet auf Basis des Mittelwertes der C-und N-Bestimmung, 0,19 m Äq Silan/g.Carrier 2, calculated on the basis of the mean value of the C and N determination, contained 0.19 m eq of silane / g.
10 g dieses Trägers wurden in 20 ml Lösung von 1 g Amyloglucosidase (Merck 1330) in 0,05 m Phosphatpuffer (pH 7) suspendiert und, wie im Beispiel 1 beschrieben, präpariert. Die fertige Probe 2.1 wies nach der C-N-Analyse einen Proteingehalt von 30,8 mg/g auf.10 g of this carrier were suspended in 20 ml solution of 1 g amyloglucosidase (Merck 1330) in 0.05 m phosphate buffer (pH 7) and prepared as described in Example 1. The finished sample 2.1 had a protein content of 30.8 mg / g after the C-N analysis.
Weitere 10 g des silanisierten Trägers 2 wurden in 20 ml Lösung von 0,5 g Amyloglucosidase (Merck 1330) in 0,05 m Phosphatpuffer (pH 7) suspendiert und, wie im Beispiel 1 (Probe 1.2) beschrieben, behandelt.
Die C-N-Analyse der fertigen Probe 2.2 ergab einen Proteingehalt von 17,4 mg/g.Another 10 g of the silanized carrier 2 were suspended in 20 ml solution of 0.5 g amyloglucosidase (Merck 1330) in 0.05 m phosphate buffer (pH 7) and treated as described in Example 1 (sample 1.2).
The CN analysis of the finished sample 2.2 showed a protein content of 17.4 mg / g.
Zur Herstellung des Trägers 3 wurde ein aus Natriumsilikatlösung mit Schwefelsäure gefälltes Si02-Gel mit einem Na20-Gehalt von 0,3 Gew.-%, wie im Beispiel 1 beschrieben, getrocknet. 1 kg dieses Materials wurde sechs Stunden bei 640°C in einem Luftstrom von 2 l/min, der einen relativen Feuchtigkeitsgehalt von 60 % aufwies, geglüht. Nach dieser Behandlung hatte das Si02 einen häufigsten Porendurchmesser von 180 Å. Der Träger 3 wurde durch Siebung in Fraktionen getrennt. Die weitere Präparation erfolgte mit der Fraktion 0,25 bis 0,50 mm.For the preparation of the support 3 a precipitated from sodium silicate solution with sulfuric acid has been described Si0 2 gel having a Na 2 0 content of 0.3 wt .-% as in Example 1 dried. 1 kg of this material was annealed for six hours at 640 ° C in an air flow of 2 l / min, which had a relative moisture content of 60%. After this treatment, the Si0 2 had a common pore diameter of 180 Å. The carrier 3 was separated into fractions by sieving. The further preparation was carried out with the fraction 0.25 to 0.50 mm.
150 g dieser Trägerfraktion wurde acht Stunden mit 4 1 einer 10 %igen Lösung von y-Aminopropyltriäthoxysilan in Benzol entsprechend dem im Beispiel 1 angegebenen Verfahren behandelt.150 g of this carrier fraction was treated for 8 hours with 4 l of a 10% solution of y-aminopropyltriethoxysilane in benzene in accordance with the procedure given in example 1.
Der Träger 3 enthielt, berechnet auf Basis des Mittelwertes der C- und N-Bestimmung 0,51 m Äq Silan/g.Carrier 3, calculated on the basis of the mean value of the C and N determination, contained 0.51 m eq of silane / g.
10 g dieses Trägers wurden in 20 ml Lösung von 1 g Amyloglucosidase (Merck 1330) in 0,05 m Phosphatpuffer (pH 7) suspendiert und, wie im Beispiel 1 beschrieben, präpariert.10 g of this carrier were suspended in 20 ml solution of 1 g amyloglucosidase (Merck 1330) in 0.05 m phosphate buffer (pH 7) and prepared as described in Example 1.
Die fertige Probe 3.1 wies nach der C-N-Analyse einen Proteingehalt von 26,2 mg/g auf. ,The finished sample 3.1 had a protein content of 26.2 mg / g after the C-N analysis. ,
Weitere 10 g des silanisierten Trägers 3 wurden in 20 ml Lösung von 0,5 g Amyloglucosidase (Merck 1330) in 0,05 m Phosphatpuffer (pH 7) suspendiert und, wie im Beispiel 1 (Probe 1.2) beschrieben, behandelt. Die C-N-Analyse der fertigen Probe 3.2 ergab einen Proteingehalt von 12,7 mg/g.A further 10 g of the silanized carrier 3 were suspended in 20 ml of a solution of 0.5 g of amyloglucosidase (Merck 1330) in 0.05 m phosphate buffer (pH 7) and treated as described in Example 1 (sample 1.2). The C-N analysis of the finished sample 3.2 showed a protein content of 12.7 mg / g.
Um den Nachweis zu führen, dass das Kupplungsmittel auf die Aktivität des Präparates keinen Einfluss hat, wurde von dem Träger 2 (häufigster Porendurchmesser 340 Å) die Fraktion 0,25-0,5 mm ausgesiebt und davon 50 g in 500 ml 12,5 %iger wäßriger Glutardialdehydlösung 5 Minuten bei Raumtemperatur gerührt. Anschliessend erfolgte ein Zusatz von 500 ml gesättigter NH4C1-Lösung. Nach vierstündigem Rühren bei Raumtemperatur wurde die Probe mit Wasser bis zur Chloridfreiheit gewaschen und über P205 im Vakuum getrocknet. 10 g dieses Trägers wurden in 20 ml Lösung von 1 g Amyloglucosidase (Merck 1330) in 0,05 m Phosphatpuffer (pH 7) suspendiert und wie im Beispiel 1 beschrieben, präpariert.In order to demonstrate that the coupling agent has no effect on the activity of the preparation, the fraction 0.25-0.5 mm was sieved from the carrier 2 (most common pore diameter 340 Å) and 50 g thereof in 500 ml 12.5 % aqueous glutardialdehyde solution stirred for 5 minutes at room temperature. 500 ml of saturated NH 4 C1 solution were then added. After four hours of stirring at room temperature, the sample was washed with water until free of chloride and dried over P 2 0 5 in vacuo. 10 g of this carrier were suspended in 20 ml solution of 1 g amyloglucosidase (Merck 1330) in 0.05 m phosphate buffer (pH 7) and prepared as described in Example 1.
Die fertige Probe 4.1 wies nach der C-N-Analyse einen Proteingehalt von 29,8 mg/g auf.The finished sample 4.1 had a protein content of 29.8 mg / g after the C-N analysis.
Weitere 10 g des Trägers 2 wurden in 20 ml Lösung von 0,5 g Amyloglucosidase (Merek 1330) in 0,05 m Phosphatpuffer (pH 7) suspendiert und wie im Beispiel 1 (Probe 1.2) beschrieben, behandelt.
Die C-N-Analyse der fertigen Probe 4.2 ergab einen Proteingehalt von 17,9 mg.Another 10 g of carrier 2 were suspended in 20 ml solution of 0.5 g amyloglucosidase (Merek 1330) in 0.05 m phosphate buffer (pH 7) and treated as described in example 1 (sample 1.2).
The CN analysis of the finished sample 4.2 showed a protein content of 17.9 mg.
10 g des Trägers 1 (häufigster Porendurchmesser 1400 Å) wurden in 40 ml einer 0,05 m Phosphatpufferlösung (pH 7), die 0,5 g Glucoseisomerase (Y.Takasaki, Agr.Biol.Chem.33, Nr. 11, 1527-1534 (1969))enthielt, suspendiert.10 g of carrier 1 (most common pore diameter 1400 Å) were in 40 ml of a 0.05 m phosphate buffer solution (pH 7), the 0.5 g glucose isomerase (Y.Takasaki, Agr.Biol.Chem.33, No. 11, 1527 -1534 (1969)), suspended.
Die Reaktionszeit betrug bei Raumtemperatur 30 Minuten. Nach jeweils 10 Minuten wurde das Reaktionsgefäss evakuiert und nach Beendigung der Reaktion die Restlösung abgesaugt. Dann erfolgten 3 Waschungen mit Wasser und 0,05 m Phosphatpuffer (pH 7).The reaction time was 30 minutes at room temperature. After every 10 minutes, the reaction vessel was evacuated and, after the reaction had ended, the residual solution was suctioned off. Then 3 washes with water and 0.05 m phosphate buffer (pH 7).
Die fertige Probe 5.1 wies nach der C-N-Analyse einen Proteingehalt von 4,8 mg/g auf.The finished sample 5.1 had a protein content of 4.8 mg / g after the C-N analysis.
Zur Herstellung der Probe 5.2 wurden weitere 10 g des Trägers 1 in 40 ml einer 0,05 m Phosphatpufferlösung (pH 7), die 0,25 g Glucoseisomerase enthielt, suspendiert. Die weitere Verfahrensweise entsprach der Präparation 5.1.To prepare sample 5.2, a further 10 g of carrier 1 were suspended in 40 ml of a 0.05 m phosphate buffer solution (pH 7) which contained 0.25 g of glucose isomerase. The further procedure corresponded to preparation 5.1.
Die C-N-Analyse der fertigen Probe 5.2 ergab einen Proteingehalt von 2,0 mg/g.The C-N analysis of the finished sample 5.2 showed a protein content of 2.0 mg / g.
10 g des Trägers2(häufigster Porendurchmesser 340 A) wurden in 40 ml einer 0,05 m Phosphatpufferlösung (pH 7), die 0,5 g Glucoseisomerase enthielt, suspendiert.10 g of the carrier 2 (most common pore diameter 340 A) were suspended in 40 ml of a 0.05 m phosphate buffer solution (pH 7), which contained 0.5 g of glucose isomerase.
Die weitere Behandlung entsprach Beispiel 5. Die fertige Probe 6.1 wies nach der C-N-Analyse einen Proteingehalt von 22,0 mg/g auf.The further treatment corresponded to Example 5. The finished sample 6.1 had a protein content of 22.0 mg / g after the C-N analysis.
Zur Herstellung der Probe 6.2 wurden weitere 10 g des Trägers 2 in 40 ml einer 0,05 m Phosphatpufferlösung (pH 7), die 0,25 g Glucoseisomerase enthielt, suspendiert. Die weitere Behandlung entsprach Beispiel 5. Die C-N-Analyse der fertigen Probe 6.2 ergab einen Proteingehalt von 10,2 mg/g.To prepare sample 6.2, a further 10 g of carrier 2 were suspended in 40 ml of a 0.05 m phosphate buffer solution (pH 7) which contained 0.25 g of glucose isomerase. The further treatment corresponded to example 5. The C-N analysis of the finished sample 6.2 showed a protein content of 10.2 mg / g.
10 g des Trägers 3 (häufigster Porendurchmesser 180 i) wurden in 40 ml einer 0,05 m Phosphatpufferlösung (pH 7), die 0,5 g Glucoseisomerase enthielt, suspendiert.10 g of the carrier 3 (most common pore diameter 180 i) were suspended in 40 ml of a 0.05 m phosphate buffer solution (pH 7), which contained 0.5 g glucose isomerase.
Die weitere Behandlung entsprach Beispiel 5. Die fertige Probe 7.1 wies nach der C-N-Analyse einen Proteingehalt von 11,2 mg/g auf.The further treatment corresponded to Example 5. The finished sample 7.1 had a protein content of 11.2 mg / g after the C-N analysis.
Zur Herstellung der Probe 7.2 wurden weitere 10 g des Trägers 3 in 40 ml einer 0,05 m Phosphatpufferlösung (pH 7), die 0,25 g Glucoseisomerase enthielt, suspendiert. Die weitere Verfahrensweise entsprach der Präparation 5.1.To prepare sample 7.2, a further 10 g of carrier 3 were suspended in 40 ml of a 0.05 m phosphate buffer solution (pH 7) which contained 0.25 g of glucose isomerase. The further procedure corresponded to preparation 5.1.
Die C-N-Analyse der fertigen Probe 7.2 ergab einen Proteingehalt von 5,1 mg/g.The C-N analysis of the finished sample 7.2 showed a protein content of 5.1 mg / g.
10 g des im Beispiel 4 genannten Trägers (häufigster Porendurchmesser 340 Ä , behandelt mit wäßriger Glutardialdehydlösung) wurden in 40 ml einer 0,05 m Phosphatpufferlösung (pH 7), die 0,5 g Glucoseisomerase enthielt, suspendiert. Die weitere Behandlung entsprach Beispiel 5. Die fertige Probe 8.1 wies nach der C-N-Analyse einen Proteingehalt von 21,3 mg/g auf.10 g of the carrier mentioned in Example 4 (most common pore diameter 340 Å, treated with aqueous glutardialdehyde solution) were suspended in 40 ml of a 0.05 M phosphate buffer solution (pH 7), which contained 0.5 g of glucose isomerase. The further treatment corresponded to Example 5. The finished sample 8.1 had a protein content of 21.3 mg / g after the C-N analysis.
Zur Herstellung der Probe 8.2 wurden weitere 10 g des gleichen Trägers in 40 ml einer 0,05 m Phosphatpufferlösung (pH 7), die 0,25 g Glucoseisomerase enthielt, suspendiert. Die weitere Verfahrensweise entsprach der Präparation 5.1. Die C-N-Analyse der fertigen Probe 8.2 ergab einen Proteingehalt von 9,8 mg/g.To prepare sample 8.2, a further 10 g of the same carrier were suspended in 40 ml of a 0.05 m phosphate buffer solution (pH 7) which contained 0.25 g of glucose isomerase. The further procedure corresponded to preparation 5.1. The C-N analysis of the finished sample 8.2 showed a protein content of 9.8 mg / g.
Die Aktivität der in den Beispielen 1 bis 4 beschriebenen Präparate 1.1, 1.2; 2.1, 2.2; 3.1, 3.2; 4.1, 4.2 sowie die des zur Fixierung eingesetzten Enzyms (Amyloglucosidase, Merck 1330) wurde nach der Dinitrosalizylsäuremethode (vergl. Rick, W., Stegbauer, H.P. in: Bergmeyer, H.U. "Meth. d. Enzymatischen Analyse", Verlag Chemie 1970 S. 848 ff) bestimmt. Eine Aktivitätseinheit (U) entspricht der Enzymmenge, die unter Inkubationsbedingungen 1µ Äquivalent reduzierende Gruppen (berechnet als Glucose) pro Minute freisetzt.The activity of the preparations 1.1, 1.2 described in Examples 1 to 4; 2.1, 2.2; 3.1, 3.2; 4.1, 4.2 and that of the enzyme used for fixation (amyloglucosidase, Merck 1330) was used according to the dinitrosalicylic acid method (see Rick, W., Stegbauer, HP in: Bergmeyer, HU "Meth. D. Enzymatic Analysis", Verlag Chemie 1970 S. 848 ff). One activity unit (U) corresponds to the amount of enzyme that releases 1µ equivalent reducing groups (calculated as glucose) per minute under incubation conditions.
2 %ige Substratlösung (Zulkowsky-Stärke Merck 1257) in 0,1 m Acetatpuffer pH 5,0, 30 Minuten, 25°C. Trägerfixierte Präparate wurden unter o.a. Bedingungen in einem 40 ml Reaktor bei einer Rührgeschwindigkeit von 600 min 1 (Produktbildungsrate unabhängig von Rührgeschwindig- . keit) suspendiert.2% substrate solution (Zulkowsky starch Merck 1257) in 0.1 m acetate buffer pH 5.0, 30 minutes, 25 ° C. Carrier-fixed preparations were suspended under the above conditions in a 40 ml reactor at a stirring speed of 600 min 1 (product formation rate regardless of stirring speed.).
Der Proteingehalt der Präparate wurde auf Basis der Mittelwerte der C-N-Bestimmung ermittelt. Der häufigste Porendurchmesser der Träger wurde aus der Porenverteilung (gemessen mit Hochdruckporosimeter) bestimmt.The protein content of the preparations was determined on the basis of the mean values of the C-N determination. The most common pore diameter of the carriers was determined from the pore distribution (measured with a high pressure porosimeter).
In der folgenden Tabelle 1 sind die Ergebnisse der Proben 1-4 zusammengestellt. Die verwendeten Kenngrössen werden wie folgt definiert:
Die Aktivität der in den Beispielen 5-8 beschriebenen Präparate 5.1, 5.2; 6.1, 6.2; 7.1, 7.2; 8.1, 8.2 sowie die der zur Fixierung eingesetzten Glucoseisomerase wurde nach der Takasaki-Methode (vgl. Y.Takasaki: Agr.Biol.Chem. Vol.30, Nr.12, 1247-1253, 1966 und Z.Dische u.E.Borenfreund: J.Biol. Chem.192, 583, 1951) bestimmt. Eine Aktivitätseinheit (U) ist definiert als die Enzymmenge, die unter Inkubationsbedingungen 1 mg Fructose bildet.The activity of the preparations 5.1, 5.2 described in Examples 5-8; 6.1, 6.2; 7.1, 7.2; 8.1, 8.2 and that of the glucose isomerase used for fixation was determined using the Takasaki method (cf. Y.Takasaki: Agr.Biol.Chem. Vol.30, No. 12, 1247-1253, 1966 and Z.Dische uEBorenfreund: J Biol. Chem. 192, 583, 1951). One unit of activity (U) is defined as the amount of enzyme that forms 1 mg of fructose under incubation conditions.
Der Proteingehalt der Präparate wurde auf Basis der Mittelwerte der C-N-Bestimmung ermittelt.The protein content of the preparations was determined on the basis of the mean values of the C-N determination.
In der folgenden Tabelle 2 sind die Ergebnisse der Proben 5-8 zusammengestellt.The results of samples 5-8 are summarized in Table 2 below.
Die Definition der verwendeten Kenngrössen ist im Beispiel 9 angegeben.
- 1. Die Aktivität U der untersuchten Proben verläuft über ein Maximum, das vom häufigsten Porendurchmesser des Trägers abhängig ist.1. The activity U of the examined samples runs over a maximum which is dependent on the most common pore diameter of the carrier.
- 2. Die spezifische Aktivität Us hängt von der Enzymaufnahme ab und erreicht bei einer bestimmten Enzymkonzentration cE den Wert der Aktivität des Enzyms im freien Zustand U SF, so dass Urel = 100 wird. Wird diese Enzymmenge überschritten, sinkt die spezifische Aktivität ab, wobei das Produkt aus Us und cE konstant bleibt.2. The specific activity U s depends on the enzyme uptake and, at a specific enzyme concentration c E, reaches the value of the activity of the enzyme in the free state U SF , so that s s U rel = 100. If this amount of enzyme is exceeded, the specific activity drops, the product of U s and c E remaining constant.
- 3. Die vom Träger aufgenommene Enzymmenge ist eine Funktion des häufigsten Porendurchmessers. Das System Enzym/Träger weist maximale Aktivität bei kleinstmöglichem Enzymeinsatz auf, wenn der optimale Träger 2 (häufigster Porendurchmesser 340 Ä) 17,4 mg Amyloglucosidase/g bzw. 10,2 mg Glucoseisomerase/g aufgenommen hat (Proben 2.2 bzw. 6.2).3. The amount of enzyme absorbed by the carrier is a function of the most common pore diameter. The enzyme / carrier system shows maximum activity with the smallest possible use of enzyme if the optimal carrier 2 (most common pore diameter 340 Å) has absorbed 17.4 mg amyloglucosidase / g or 10.2 mg glucose isomerase / g (samples 2.2 and 6.2).
- 4. Enzymaufnahme und Aktivität der untersuchten Proben sind vom Kupplungsmittel unabhängig.4. Enzyme uptake and activity of the samples examined are independent of the coupling agent.
Da die Enzymkosten beträchtlich sind und mit dem geforderten Reinheitsgrad sehr stark ansteigen, für den wirtschaftlichen Einsatz also eine erhebliche Rolle spielen, ist mit dem erfindungsgemässen Verfahren erstmals die Möglichkeit geschaffen worden, auch teure Enzyme technisch anzuwenden, da es das Verfahren gestattet, bei Einsatz des erfindungsgemässen Trägers, die für maximale Aktivität benötigte Enzymmenge zu optimieren.Since the enzyme costs are considerable and increase very strongly with the required degree of purity, i.e. they play a significant role for economic use, the method according to the invention has for the first time made it possible to use expensive enzymes technically, since the method allows the use of carrier according to the invention to optimize the amount of enzyme required for maximum activity.
Claims (11)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2726188 | 1977-06-10 | ||
| DE2726188A DE2726188C2 (en) | 1977-06-10 | 1977-06-10 | Process for the production of a water-insoluble enzyme preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP0000028A1 true EP0000028A1 (en) | 1978-12-20 |
| EP0000028B1 EP0000028B1 (en) | 1981-04-22 |
Family
ID=6011173
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP78100045A Expired EP0000028B1 (en) | 1977-06-10 | 1978-06-01 | Process for the preparation of a water-insoluble enzyme composition |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US4230803A (en) |
| EP (1) | EP0000028B1 (en) |
| JP (1) | JPS548789A (en) |
| AR (1) | AR222972A1 (en) |
| AU (1) | AU517551B2 (en) |
| BE (1) | BE868020A (en) |
| BG (1) | BG28720A3 (en) |
| CA (1) | CA1100066A (en) |
| CS (1) | CS216234B2 (en) |
| DD (1) | DD135495A5 (en) |
| DE (2) | DE2726188C2 (en) |
| DK (1) | DK149757C (en) |
| ES (1) | ES470069A1 (en) |
| FI (1) | FI62139C (en) |
| FR (1) | FR2393810A1 (en) |
| GB (1) | GB1600339A (en) |
| HU (1) | HU179727B (en) |
| IT (1) | IT1094879B (en) |
| NL (1) | NL7805996A (en) |
| PL (1) | PL126637B1 (en) |
| RO (1) | RO74644A (en) |
| SE (1) | SE7806679L (en) |
| YU (1) | YU137078A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2393810A1 (en) * | 1977-06-10 | 1979-01-05 | Kali Chemie Ag | PROCESS FOR THE PRODUCTION OF WATER INSOLUBLE ENZYMATIC PREPARATIONS AND PREPARATIONS OBTAINED ACCORDING TO THIS PROCESS |
| EP0081185A1 (en) * | 1981-12-09 | 1983-06-15 | Kali-Chemie Aktiengesellschaft | Process and apparatus for the preparation of isomerose |
| FR2525629A1 (en) * | 1982-04-27 | 1983-10-28 | Ags Bmp Argiles Mineraux | Silico-aluminate ceramic support for immobilised enzymes and organisms - contains magnesia, has controlled particle size and pref. at least 50 per cent cordierite crystallographic structure |
| EP0158909A3 (en) * | 1984-04-14 | 1986-10-29 | Redco N.V. | Immobilized enzymes, processes for preparing same and use thereof |
| EP0152036A3 (en) * | 1984-02-13 | 1987-01-21 | Kali-Chemie Aktiengesellschaft | Process for preparing isoglucose |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0093027A1 (en) * | 1982-04-27 | 1983-11-02 | ARGILES & MINERAUX AGS-BMP | Carrier for the fixation of microorganisms |
| US4530963A (en) * | 1982-08-20 | 1985-07-23 | Devoe-Holbein International, N.V. | Insoluble chelating compositions |
| US4654322A (en) * | 1985-08-05 | 1987-03-31 | Devoe-Holbein International, N.V. | Insoluble compositions for removing mercury from a liquid medium |
| US4749653A (en) * | 1985-10-21 | 1988-06-07 | Owens-Corning Fiberglas Corporation | Enzyme immobilization on non-porous glass fibers |
| DE3719324C1 (en) * | 1987-06-10 | 1988-12-15 | Kali Chemie Ag | Process for the production of carrier-bound enzymes |
| US5504042A (en) * | 1994-06-23 | 1996-04-02 | Texas Instruments Incorporated | Porous dielectric material with improved pore surface properties for electronics applications |
| US5753305A (en) * | 1995-11-16 | 1998-05-19 | Texas Instruments Incorporated | Rapid aging technique for aerogel thin films |
| US6380105B1 (en) | 1996-11-14 | 2002-04-30 | Texas Instruments Incorporated | Low volatility solvent-based method for forming thin film nanoporous aerogels on semiconductor substrates |
| US6063714A (en) * | 1995-11-16 | 2000-05-16 | Texas Instruments Incorporated | Nanoporous dielectric thin film surface modification |
| US6130152A (en) | 1995-11-16 | 2000-10-10 | Texas Instruments Incorporated | Aerogel thin film formation from multi-solvent systems |
| US5807607A (en) * | 1995-11-16 | 1998-09-15 | Texas Instruments Incorporated | Polyol-based method for forming thin film aerogels on semiconductor substrates |
| US6037277A (en) * | 1995-11-16 | 2000-03-14 | Texas Instruments Incorporated | Limited-volume apparatus and method for forming thin film aerogels on semiconductor substrates |
| US6319852B1 (en) | 1995-11-16 | 2001-11-20 | Texas Instruments Incorporated | Nanoporous dielectric thin film formation using a post-deposition catalyst |
| US5736425A (en) * | 1995-11-16 | 1998-04-07 | Texas Instruments Incorporated | Glycol-based method for forming a thin-film nanoporous dielectric |
| CA2353307A1 (en) | 2001-07-13 | 2003-01-13 | Carmen Parent | Device and procedure for processing gaseous effluents |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2020527A1 (en) * | 1968-09-05 | 1970-07-17 | Corning Glass Works | |
| FR2223324A1 (en) * | 1973-03-26 | 1974-10-25 | Corning Glass Works | |
| FR2273008A1 (en) * | 1974-05-28 | 1975-12-26 | Corning Glass Works |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3850751A (en) * | 1973-02-16 | 1974-11-26 | Corning Glass Works | Enzymes immobilized on porous inorganic support materials |
| DE2726188C2 (en) * | 1977-06-10 | 1979-05-10 | Kali-Chemie Ag, 3000 Hannover | Process for the production of a water-insoluble enzyme preparation |
-
1977
- 1977-06-10 DE DE2726188A patent/DE2726188C2/en not_active Expired
-
1978
- 1978-05-05 BG BG039644A patent/BG28720A3/en unknown
- 1978-05-22 ES ES470069A patent/ES470069A1/en not_active Expired
- 1978-05-29 AR AR272349A patent/AR222972A1/en active
- 1978-05-30 GB GB24510/78A patent/GB1600339A/en not_active Expired
- 1978-05-30 IT IT23967/78A patent/IT1094879B/en active
- 1978-05-31 US US05/911,227 patent/US4230803A/en not_active Expired - Lifetime
- 1978-06-01 EP EP78100045A patent/EP0000028B1/en not_active Expired
- 1978-06-01 DE DE7878100045T patent/DE2860632D1/en not_active Expired
- 1978-06-01 NL NL7805996A patent/NL7805996A/en not_active Application Discontinuation
- 1978-06-05 RO RO7894265A patent/RO74644A/en unknown
- 1978-06-05 HU HU78KA1505A patent/HU179727B/en not_active IP Right Cessation
- 1978-06-05 FR FR787816697A patent/FR2393810A1/en active Pending
- 1978-06-07 FI FI781821A patent/FI62139C/en not_active IP Right Cessation
- 1978-06-07 CS CS783707A patent/CS216234B2/en unknown
- 1978-06-08 DD DD78205886A patent/DD135495A5/en not_active IP Right Cessation
- 1978-06-08 AU AU36926/78A patent/AU517551B2/en not_active Expired
- 1978-06-08 CA CA305,057A patent/CA1100066A/en not_active Expired
- 1978-06-08 YU YU01370/78A patent/YU137078A/en unknown
- 1978-06-08 SE SE7806679A patent/SE7806679L/en unknown
- 1978-06-09 JP JP6973078A patent/JPS548789A/en active Granted
- 1978-06-09 PL PL1978207511A patent/PL126637B1/en unknown
- 1978-06-09 BE BE6046498A patent/BE868020A/en unknown
- 1978-06-09 DK DK257678A patent/DK149757C/en not_active IP Right Cessation
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2020527A1 (en) * | 1968-09-05 | 1970-07-17 | Corning Glass Works | |
| FR2223324A1 (en) * | 1973-03-26 | 1974-10-25 | Corning Glass Works | |
| FR2273008A1 (en) * | 1974-05-28 | 1975-12-26 | Corning Glass Works |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2393810A1 (en) * | 1977-06-10 | 1979-01-05 | Kali Chemie Ag | PROCESS FOR THE PRODUCTION OF WATER INSOLUBLE ENZYMATIC PREPARATIONS AND PREPARATIONS OBTAINED ACCORDING TO THIS PROCESS |
| EP0081185A1 (en) * | 1981-12-09 | 1983-06-15 | Kali-Chemie Aktiengesellschaft | Process and apparatus for the preparation of isomerose |
| FR2525629A1 (en) * | 1982-04-27 | 1983-10-28 | Ags Bmp Argiles Mineraux | Silico-aluminate ceramic support for immobilised enzymes and organisms - contains magnesia, has controlled particle size and pref. at least 50 per cent cordierite crystallographic structure |
| EP0152036A3 (en) * | 1984-02-13 | 1987-01-21 | Kali-Chemie Aktiengesellschaft | Process for preparing isoglucose |
| EP0158909A3 (en) * | 1984-04-14 | 1986-10-29 | Redco N.V. | Immobilized enzymes, processes for preparing same and use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS6133557B2 (en) | 1986-08-02 |
| DE2860632D1 (en) | 1981-07-30 |
| FI781821A7 (en) | 1978-12-11 |
| PL126637B1 (en) | 1983-08-31 |
| FR2393810A1 (en) | 1979-01-05 |
| HU179727B (en) | 1982-11-29 |
| YU137078A (en) | 1983-02-28 |
| ES470069A1 (en) | 1979-01-01 |
| US4230803A (en) | 1980-10-28 |
| FI62139B (en) | 1982-07-30 |
| AU517551B2 (en) | 1981-08-06 |
| PL207511A1 (en) | 1979-05-07 |
| RO74644A (en) | 1980-10-30 |
| GB1600339A (en) | 1981-10-14 |
| DE2726188B1 (en) | 1978-08-31 |
| NL7805996A (en) | 1978-12-12 |
| AU3692678A (en) | 1979-12-13 |
| SE7806679L (en) | 1978-12-11 |
| FI62139C (en) | 1982-11-10 |
| IT7823967A0 (en) | 1978-05-30 |
| DE2726188C2 (en) | 1979-05-10 |
| BE868020A (en) | 1978-12-11 |
| EP0000028B1 (en) | 1981-04-22 |
| DD135495A5 (en) | 1979-05-09 |
| IT1094879B (en) | 1985-08-10 |
| DK149757C (en) | 1987-03-02 |
| JPS548789A (en) | 1979-01-23 |
| CS216234B2 (en) | 1982-10-29 |
| CA1100066A (en) | 1981-04-28 |
| BG28720A3 (en) | 1980-06-16 |
| AR222972A1 (en) | 1981-07-15 |
| DK149757B (en) | 1986-09-22 |
| DK257678A (en) | 1978-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0000028B1 (en) | Process for the preparation of a water-insoluble enzyme composition | |
| DE69420390T2 (en) | Hydrolysis of coffee with immobilized beta-mannanase | |
| DE69024812T2 (en) | METHOD FOR THE HYDROLYSIS OF HEMICELLULOSE BY IMMOBILIZED ENZYMS AND A PRODUCT CONSTRUCTING AN IMMOBILIZED HEMIZELLULYTIC ENZYME | |
| DE2839170C2 (en) | Chromatographic material | |
| DE3336257C2 (en) | ||
| DE3520001C2 (en) | Process for the production of immobilized microorganisms or enzymes | |
| DE3688493T2 (en) | IMMOBILIZATION OF BIOCATALYSTS ON GRAINY PEBBLES. | |
| EP0200107B1 (en) | Process for the immobilization of dissolved proteins | |
| DE2705377C2 (en) | ||
| DE2806674B2 (en) | Immobilized enzymes | |
| DE2522484A1 (en) | PROCESS FOR MANUFACTURING A PRODUCT WITH ENZYMATIC ACTIVITY | |
| DE2717965A1 (en) | POROESE CELLULOSE BEADS | |
| DE3801053C2 (en) | ||
| DE4429018C2 (en) | A process for producing an enzyme immobilizing carrier, regenerated porous chitosan carrier in particulate form and use of the carrier | |
| DE3721441C1 (en) | Process for the preparation of an apatite with glucanase immobilized thereon and apatites produced by the process | |
| DE69002459T2 (en) | IMMOBILIZED LIPASE PRODUCTION AND THEIR USE FOR PRODUCING ESTERS. | |
| CH618466A5 (en) | ||
| DE3719324C1 (en) | Process for the production of carrier-bound enzymes | |
| WO1995016773A1 (en) | Substrate-fixed penicillin g amidase, glutaryl-7-aca acylase or d-aminoacid oxidase | |
| DE4005927A1 (en) | IMMOBILIZATION OF PROTEINS TO TRAEGERS | |
| DE2439923B2 (en) | METHOD OF FIXING ENZYMES ON A CARRIER MATERIAL | |
| DE2821890A1 (en) | PROCESS FOR THE REGENERATION OF ENZYME REAL ESTATE | |
| DE2805366C2 (en) | ||
| DD260292A1 (en) | PROCESS FOR THE ISOLATION AND PURIFICATION OF BETA LACTAMASES | |
| DE2206636B2 (en) | Reactive matrix for the separation of enzymes present in a medium and use of the same for the affinity chromatographic separation of enzymes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): BE CH DE FR GB LU NL SE |
|
| 17P | Request for examination filed | ||
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): BE CH DE FR GB LU NL SE Designated state(s): BE CH DE FR GB LU NL SE |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19810630 |
|
| REF | Corresponds to: |
Ref document number: 2860632 Country of ref document: DE Date of ref document: 19810730 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 19900517 Year of fee payment: 13 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 19900518 Year of fee payment: 13 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 19900523 Year of fee payment: 13 Ref country code: LU Payment date: 19900523 Year of fee payment: 13 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 19900525 Year of fee payment: 13 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 19900529 Year of fee payment: 13 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 19900630 Year of fee payment: 13 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 19900709 Year of fee payment: 13 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Effective date: 19910601 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Effective date: 19910602 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Effective date: 19910630 Ref country code: BE Effective date: 19910630 |
|
| BERE | Be: lapsed |
Owner name: KALI-CHEMIE A.G. Effective date: 19910630 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Effective date: 19920101 |
|
| GBPC | Gb: european patent ceased through non-payment of renewal fee | ||
| NLV4 | Nl: lapsed or anulled due to non-payment of the annual fee | ||
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Effective date: 19920228 |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Effective date: 19920401 |
|
| REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST |
|
| EUG | Se: european patent has lapsed |
Ref document number: 78100045.0 Effective date: 19920109 |
|
| PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |